What the FDA labels say about taking them together
Dofetilide and dolutegravir
Dofetilide's FDA label of April 21, 2026 names dolutegravir in its contraindications section, and dolutegravir's label names dofetilide too. The dolutegravir label: “Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1.”
Check it at the source: the dofetilide FDA label on DailyMed (effective April 21, 2026, Pfizer Laboratories Div Pfizer Inc); the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY).
What does the dofetilide label say about dolutegravir?
Dofetilide label, contraindicationsIn addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on TIKOSYN.
Source: FDA drug label (Tikosyn), Pfizer Laboratories Div Pfizer Inc, effective April 21, 2026 (SPL set 02438044-d6a3-49e9-a1ac-3aad21ef2c8c), via openFDA; the full label on DailyMed
What does the dolutegravir label say about dofetilide?
Dolutegravir label, contraindicationsCONTRAINDICATIONS TIVICAY and TIVICAY PD are contraindicated in patients: with previous hypersensitivity reaction to dolutegravir [see Warnings and Precautions ( 5.1 )]. receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see Drug Interactions ( 7 )].
Dolutegravir label, drug interactionsDolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin, Table 8 ) [see Contraindications ( 4 ), Drug Interactions ( 7.3 )].
Tivicay Pd label (ViiV Healthcare Company, August 25, 2026), contraindications• receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see Drug Interactions ( 7 )].
Source: FDA drug label (Tivicay Pd, NDA213983), ViiV Healthcare Company, effective August 25, 2026 (SPL set 63df5af3-b8ac-4e76-9830-2dbb340af922), via openFDA
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dofetilide | Dolutegravir | |
|---|---|---|
| Labeled for | Atrial fibrillation | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.203 per capsule 125 mcg capsule | $77.64 per tablet 50 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once